All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today)